Wednesday, July 8, 2026

Drug profile · INN

hyaluronidase recombinant human

hyaluronidase recombinant human (HYLENEX RECOMBINANT) is a hyaluronic acid hydrolytic enzyme. Associated with HALOZYME THERAPEUTICS, INC.. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 16
Pipeline programs 4
News articles 0
Drug details — hyaluronidase recombinant human
US status
approved
Class
Route
INJECTION
Patents
16
Programs
4
Data quality
0.89

Quick answer

hyaluronidase recombinant human (HYLENEX RECOMBINANT) is a hyaluronic acid hydrolytic enzyme. Associated with HALOZYME THERAPEUTICS, INC.. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN hyaluronidase recombinant human
Brand HYLENEX RECOMBINANT
Mechanism Hyaluronic acid hydrolytic enzyme
Target Hyaluronic acid
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Hyaluronic acid hydrolytic enzyme

Primary target: Hyaluronic acid

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Hylenex Phase 3 · HALOZYME THERAPEUTICS · Pain
  2. 1838-009 Approved · HALOZYME THERAPEUTICS · Dehydration
  3. Commercial Hylenex® recombinant (hyaluronidase human injection) Approved · HALOZYME THERAPEUTICS · Type 1 Diabetes Mellitus
  4. Hylenex Approved · HALOZYME THERAPEUTICS · Healthy

Related & competitor drugs

  1. hyaluronidase Hyaluronic acid hydrolytic enzyme
  1. US 12371685

    PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12077791

    PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10588983

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 10016491

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9683985

    Methods for assessing and identifying or evolving conditionally active therapeutic proteins

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 9211315

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8927249

    Extended soluble PH20 polypeptides and uses thereof

    Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8815558

    Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8580252

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8257699

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Aug 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8105586

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 7871607

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Jan 13 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 7846431

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 7829081

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Nov 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 7718428

    Myeloid colony stimulating factor and uses thereof

    Expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 7544499

    Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof

    Expires Mon Jun 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is hyaluronidase recombinant human?

hyaluronidase recombinant human (HYLENEX RECOMBINANT) is a hyaluronic acid hydrolytic enzyme. Associated with HALOZYME THERAPEUTICS, INC.. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for hyaluronidase recombinant human?

HYLENEX RECOMBINANT is a marketed brand name for hyaluronidase recombinant human. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of hyaluronidase recombinant human?

hyaluronidase recombinant human has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.